Quibim, a Spanish startup that’s developing foundational AI models for medical imaging spanning oncology, immunology, neurology, and metabolic disorders, has raised $50 million in a Series A round of funding.
The cash injection comes as AI makes ever deeper inroads into healthcare, spanning everything from drug discovery to clinical trials.
Quibim, for its part, is setting out to enhance diagnostic accuracy and disease detection from visual data procured from X-rays, CT scans, and MRIs. The company’s flagship product, QP-Prostate, is designed to improve prostate cancer detection, with separate products in the works for the brain, liver, breast, and lung.
Separately, Quibim also offers QP-Insights for processing multi-omics data (i.e. different types of biological data), for example in clinical trials and related studies.
Quibim says its longer-term plan is to create digital twins of the entire human body, serving “dynamic models” that help the medical community better understand the human body. That all begins at the “organ and lesion level,” as demonstrated by QP-Prostate.
Plans to grow in the U.S.
Valencia-based Quibim has now raised around $70 million since its inception, and with its latest funding, the company says it plans to double-down on its U.S. expansion plans. Indeed, Quibim received FDA 510(k) clearance back in 2023 to market its QP-Prostate product; it also hired its first chief medical officer in the U.S.
At the time of writing, Quibim says it has 170 installations globally, with partners including Stanford University and Harvard-affiliated integrated healthcare system Mass General Brigham. Separately, Philips previously announced plans to integrate Quibim’s AI models into its scanners.
Quibim’s Series A round was led by Spanish venture capital firm Asabys and private equity firm Buenavista, with participation from a slew of institutional and individual investors, including: Amadeus Capital Partners, Apex Ventures, Partech, and iPod and iPhone co-creator Tony Fadell.
“Quibim’s mission is to turn imaging into a catalyst for precision health,” Quibim CEO and co-founder Ángel Alberich-Bayarri said in a statement. “Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes.”
